Back
Cartesian Therapeutics, Inc. Stock Predictions
Share Price Moved. Momentum Hasn't Slowed.
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi
Sell
23
RNAC
Cartesian Therapeutics, Inc.
Last Price:
$7.32
Seasonality Move:
0.08%
7 Day Trial
ALL ACCESS PASS
$
7
14K Investors Got In Earlier. You Still Can.
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radiCartesian Therapeutics, Inc. Stock Forecast
-
Over the next 52 weeks, Cartesian Therapeutics, Inc. has on average historically fallen by 18% based on the past 9 years of stock performance.
-
Cartesian Therapeutics, Inc. has fallen lower in 7 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 77.78%
-
Is Cartesian Therapeutics, Inc. Stock Undervalued?The current Cartesian Therapeutics, Inc. [RNAC] share price is $7.43. The Score for RNAC is 23, which is 54% below its historic median score of 50, and infers higher risk than normal.
-
RNAC is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.
Will Cartesian Therapeutics, Inc. Stock Go Up Next Year?
-
Over the next 52 weeks, Cartesian Therapeutics, Inc. has on average historically fallen by 18% based on the past 9 years of stock performance.
Cartesian Therapeutics, Inc. Stock Rating
Sell
23
Cartesian Therapeutics, Inc. (RNAC)
is a Sell
Is Cartesian Therapeutics, Inc. overpriced?
-
Cartesian Therapeutics, Inc. has fallen lower in 7 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 77.78%
Cartesian Therapeutics, Inc. Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
cartesiantherapeutics.com
52-Week Data
52-Week High:
20.30
52-Week Low:
5.98
Prediction Charts
Market Cap:
193.2M
Price in USD:
7.43
Volume:
160.2K
Beta:
0.85
Technical Analysis
SMA50:
8.10
SMA100:
9.36
SMA200:
10.70
52-Wk Change:
-59.42%
Stock Predictions
-
Is Cartesian Therapeutics, Inc. stock public?Yes, Cartesian Therapeutics, Inc. is a publicly traded company.
-
What is the Cartesian Therapeutics, Inc. stock quote today?The Cartesian Therapeutics, Inc. stock price is 7.43 USD today.
-
How to buy Cartesian Therapeutics, Inc. stock online?You can buy Cartesian Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Nov-28 | 7.62 | 7.49 | 7.73 | 7.44 |
| Dec-1 | 7.41 | 7.30 | 7.57 | 7.20 |
| Dec-2 | 7.31 | 6.71 | 7.31 | 6.60 |
| Dec-3 | 6.72 | 6.65 | 6.94 | 6.58 |
| Dec-4 | 6.62 | 6.90 | 7.00 | 6.53 |
| Dec-5 | 6.93 | 6.88 | 7.08 | 6.80 |
| Dec-8 | 6.97 | 6.72 | 7.35 | 6.66 |
| Dec-9 | 7.16 | 7.90 | 8.40 | 7.11 |
| Dec-10 | 7.96 | 7.85 | 8.18 | 7.61 |
| Dec-11 | 7.83 | 8.45 | 8.62 | 7.74 |
| Dec-12 | 8.44 | 8.52 | 8.75 | 8.20 |
| Dec-15 | 8.53 | 8.97 | 9.23 | 8.43 |
| Dec-16 | 8.93 | 8.29 | 8.97 | 7.86 |
| Dec-17 | 8.28 | 7.43 | 8.36 | 7.38 |
Cartesian Therapeutics, Inc. Earnings
Cartesian Therapeutics, Inc. Earnings Report: Per Share Cartesian Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.
Cartesian Therapeutics, Inc. Forecast Revenue Growth
Cartesian Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Cartesian Therapeutics, Inc. and historical quarterly revenue growth:
-
Analysts estimate an earnings increase this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, an increase this year of $2.19 per share, and a decrease next year of $0.65 per share.
* Cartesian Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.